Market Size of France Blood Glucose Monitoring Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 0.87 Billion |
Market Size (2029) | USD 1.31 Billion |
CAGR (2024 - 2029) | 8.50 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France Blood Glucose Monitoring Market Analysis
The France Blood Glucose Monitoring Market size is estimated at USD 0.87 billion in 2024, and is expected to reach USD 1.31 billion by 2029, growing at a CAGR of 8.5% during the forecast period (2024-2029).
One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the coronavirus disease-2019 (COVID-19) pandemic epidemic. Diabetes has previously been identified as a significant risk factor for death in individuals infected with either the Middle East respiratory syndrome-related coronavirus (MERS-CoV) or the 2009 H1N1 pandemic influenza. More recently, one of the main comorbidities linked to COVID-19 has consistently been diabetes.
Diabetes has the highest prevalence among all chronic conditions covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region. According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people. Furthermore, approximately 0.26 million are estimated to live with Type 1 diabetes in the region. Thus, the rising prevalence of diabetes and obesity, growing awareness, regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes care devices in France. In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applies to all of the countries. For diabetes technological devices in France, the reimbursement is based on the tariff system.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.